Pharmaron, an R&D service provider for the life sciences industry with operations in China, the U.S., and the U.K., reports that it has entered into an agreement to acquire Allergan Biologics (ABL) in Liverpool from AbbVie for $118.7 million in cash. The deal is set to close in the second quarter of 2021.
The ABL site consists of a cGMP biomanufacturing facility that has held MHRA biologic manufacturing license accreditation since 2007.
The deal comes four months after Pharmaron announced its acquisition of Absorptions Systems, and will expand on their cell and gene therapy (CGT) capabilities.
“We are pleased to have the ABL site join the Pharmaron Group,” said Boliang Lou, PhD, chairman and CEO of Pharmaron. “We have been impressed with the CGT focused process R&D and complex biologic manufacturing capabilities of the ABL site, as well as the abilities that the highly experienced scientific, technical and managerial teams have demonstrated.
“The addition of this platform to Pharmaron will further strengthen our CGT services platform and allow us to better serve our partners’ needs in these exciting and emerging therapies. We are committed to further expanding capabilities and capacities at the Liverpool site to meet growing unmet demand.”
